Refine
Language
- English (2) (remove)
Is part of the Bibliography
- yes (2) (remove)
Keywords
- prostate cancer (2) (remove)
When patients recover from disease-related functional limitations, support received from partners may not always match patients' changing independence goals. The lines of defense (LoD) model proposes a hierarchy of independence goals (LoDs), ranging from minimising discomfort by disengagement (lowest LoD) to protection of self-reliance (highest LoD). Prostate cancer patients' LoDs were examined as moderators of the association between partner support and patients' and partners' affect during patients' recovery from postsurgical functional limitations. MethodsData from 169 couples were assessed four times within 7months following patients' surgery. Patients reported on post-surgery functional limitations (i.e. incontinence), LoDs, affect, and received partner support. Partners reported on affect and support provided to patients. ResultsIn patients endorsing lower LoDs, more received support was associated with less negative affect. Also, not endorsing high LoDs while receiving strong partner support was related to patients' lower negative and higher positive affect. Partners' support provision to patients tended to be associated with increases in partners' negative affect when patients had endorsed higher LoDs and with increases in positive affect when patients had endorsed lower LoDs. Matching patients' independence goals or LoDs with partners' support may be beneficial for patients' and partners' affect.
Background:
First metabolomics studies have indicated that metabolic fingerprints from accessible tissues might
be useful to better understand the etiological links between metabolism and cancer. However, there is still a lack
of prospective metabolomics studies on pre-diagnostic metabolic alterations and cancer risk.
Methods:
Associations between pre-diagnostic levels of 120 circulating metabolites (acylcarnitines, amino acids,
biogenic amines, phosphatidylcholines, sphingolipids, and hexoses) and the risks of breast, prostate, and colorectal
cancer were evaluated by Cox regression analyses using data of a prospective case-cohort study including 835
incident cancer cases.
Results:
The median follow-up duration was 8.3 years among non-cases and 6.5 years among incident cases of
cancer. Higher levels of lysophosphatidylcholines (lysoPCs), and especially lysoPC a C18:0, were consistently related
to lower risks of breast, prostate, and colorectal cancer, independent of background factors. In contrast, higher
levels of phosphatidylcholine PC ae C30:0 were associated with increased cancer risk. There was no heterogeneity
in the observed associations by lag time between blood draw and cancer diagnosis.
Conclusion:
Changes in blood lipid composition precede the diagnosis of common malignancies by several years.
Considering the consistency of the present results across three cancer types the observed alterations point to a
global metabolic shift in phosphatidylcholine metabolism that may drive tumorigenesis.